taniborbactam

bicyclic boronate that is a beta-lactamase inhibitor

Also Known As:

(3R)-3-(((trans-4-((2-Aminoethyl)amino)cyclohexyl)acetyl)amino)-2-hydroxy-3,4-dihydro-2H-1,2-benzoxaborinine-8-carboxylic acid; 2H-1,2-Benzoxaborin-8-carboxylic acid, 3-((2-(trans-4-((2-aminoethyl)amino)cyclohexyl)acetyl)amino)-3,4-dihydro-2-hydroxy-, (3R)-; VNRX-5133

Networked: 20 relevant articles (3 outcomes, 6 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Nicolau, David P: 4 articles (01/2023 - 12/2020)
2.	Henkel, Tim: 3 articles (02/2024 - 10/2021)
3.	Moeck, Greg: 3 articles (02/2024 - 01/2020)
4.	Bassetti, Matteo: 2 articles (05/2024 - 11/2020)
5.	Six, David A: 2 articles (11/2023 - 01/2020)
6.	Abdelraouf, Kamilia: 2 articles (01/2023 - 12/2020)
7.	Asempa, Tomefa E: 2 articles (01/2023 - 01/2022)
8.	Dowell, James A: 2 articles (01/2022 - 10/2021)
9.	Benvenuti, Manuela: 2 articles (01/2020 - 01/2020)
10.	Burns, Christopher J: 2 articles (01/2020 - 01/2020)

Related Diseases

1.	Infections 12/01/2020 - "Using a neutropenic murine thigh infection model, we aimed to determine the pharmacokinetic/pharmacodynamic index, relative to taniborbactam exposure, that correlated most closely with the efficacy of the cefepime/taniborbactam combination and the magnitude of index required for efficacy against serine-β-lactamase-producing strains. " 05/10/2024 - "A major area of interest in real-world application of cefepime/taniborbactam is its potential role in treating carbapenem-resistant infections, which deserves further investigation." 05/10/2024 - "Cefepime-taniborbactam and CERTAIN-1: Can we treat carbapenem-resistant infections?" 01/01/2022 - "Taniborbactam, an investigational β-lactamase inhibitor that is active against both serine- and metallo-β-lactamases, is being developed in combination with cefepime to treat serious infections caused by multidrug-resistant Gram-negative bacteria. " 11/01/2021 - "The combinations cefepime-taniborbactam and meropenem-taniborbactam are promising alternative treatment options for infections by MBL-producing isolates."
2.	Urinary Tract Infections (Urinary Tract Infection) 12/01/2022 - "Cefepime-taniborbactam possesses in-vitro potency against a range of troubling pathogens and we await further information on a recently completed study on complicated urinary tract infection. " 12/01/2020 - "In combination with cefepime, the bicyclic boronate taniborbactam is in phase 3 clinical trials for treatment of complicated urinary tract infections. " 02/15/2024 - "Cefepime-Taniborbactam in Complicated Urinary Tract Infection." 01/01/2022 - "Clinical exposure-response relationship of cefepime/taniborbactam against Gram-negative organisms in the murine complicated urinary tract infection model." 01/01/2020 - "Taniborbactam's superior breadth of activity, when paired with cefepime or meropenem, suggests these β-lactam/β-lactamase inhibitor combinations could be promising candidates for treating urinary tract infections caused by ESBL and/or AmpC, KPC or NDM-producing Enterobacteriaceae or P. "
3.	Febrile Neutropenia 04/01/2024 - "Further studies are warranted to explore the efficacy of cefepime/taniborbactam for empirical initial treatment of GNB infections in cancer patients with high rates of febrile neutropenia requiring hospitalization."
4.	Neoplasms (Cancer) 04/01/2024 - "This study evaluated in vitro activity of cefepime/taniborbactam and comparator agents against GNB pathogens isolated from patients with cancer at our institution. " 04/01/2024 - "A total of 270 GNB pathogens (2019-23) isolated from patients with cancer were tested against cefepime/taniborbactam and comparator agents commonly used for these patients. " 04/01/2024 - "In vitro activity of cefepime/taniborbactam and comparator agents against Gram-negative bacterial bloodstream pathogens recovered from patients with cancer." 04/01/2024 - "Further studies are warranted to explore the efficacy of cefepime/taniborbactam for empirical initial treatment of GNB infections in cancer patients with high rates of febrile neutropenia requiring hospitalization." 04/01/2024 - "Our results showed that taniborbactam in combination with cefepime improved in vitro activity against GNB pathogens isolated from patients with cancer, including MDR Pseudomonas aeruginosa, carbapenem-resistant Enterobacterales, ESBL-producing Enterobacterales and Stenotrophomonas maltophilia isolates, with highest activity compared with all tested comparator agents, including other β-lactam/β-lactamase inhibitor combinations. "
5.	Pyelonephritis 02/15/2024 - "Cefepime-taniborbactam was superior to meropenem for the treatment of complicated UTI that included acute pyelonephritis, with a safety profile similar to that of meropenem. " 02/15/2024 - "In this phase 3, double-blind, randomized trial, we assigned hospitalized adults with complicated urinary tract infection (UTI), including acute pyelonephritis, in a 2:1 ratio to receive intravenous cefepime-taniborbactam (2.5 g) or meropenem (1 g) every 8 hours for 7 days; this duration could be extended up to 14 days in case of bacteremia. " 05/10/2024 - "Wagenlehner and colleagues1 demonstrated non-inferiority and superiority with respect to a primary endpoint of composite success (microbiological plus clinical) of cefepime/taniborbactam vs. meropenem in treating complicated urinary tract infections and acute pyelonephritis caused by carbapenem-susceptible gram-negative bacteria in adults. "

Related Drugs and Biologics

1.	Cefepime (Maxipime)
2.	Carbapenems (Carbapenem Antibiotics)
3.	Meropenem (Merrem)
4.	Serine (L-Serine)
5.	Lactams
6.	Boron
7.	QPX7728
8.	vaborbactam
9.	Tazobactam Drug Combination Piperacillin (Zosyn)
10.	enmetazobactam